Pyxis Oncology, Inc. (NASDAQ: PYXS) had its price target raised by analysts at Royal Bank of Canada from $7.00 to $10.00. They now have an "outperform" rating on the stock.
Pyxis Oncology, Inc. (NASDAQ: PYXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Pyxis Oncology, Inc. (NASDAQ: PYXS) was downgraded by analysts at William Blair from an "outperform" rating to a "market perform" rating.
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data [Yahoo! Finance]
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data